NEW YORK (AP) — U.S. pharmaceutical large Pfizer signed a deal to buy development-stage weight problems drugmaker Metsera Inc., profitable a bidding warfare in opposition to Novo Nordisk, the Danish drugmaker behind weight-loss therapies Ozempic and Wegovy.
Metsera, primarily based in New York, has no merchandise available on the market, however it’s growing oral and injectable therapies. That features some potential therapies that would goal profitable fields for weight problems and diabetes.
The deal comes as Pfizer is making an attempt to develop its personal stake in that market, a number of months after ending improvement of a possible capsule therapy for weight problems.
In a press release issued Friday, Metsera stated Pfizer will purchase the corporate for as much as $86.25 per share, consisting of $65.60 per share in money and a contingent worth proper entitling holders to further funds of as much as $20.65 per share in money.
Associated Movies
Metsera cited U.S. antitrust dangers in Novo’s bid, saying in its assertion that the board has decided Pfizer’s revised phrases symbolize “the perfect transaction for shareholders, each from the attitude of worth and certainty of closing.”
Get weekly well being information
Obtain the newest medical information and well being info delivered to you each Sunday.
The deal comes three days after Novo Nordisk raised the stakes in its push to outbid Pfizer, saying Tuesday it will supply to pay as a lot as $10 billion for Metsera. That was larger than its earlier bid of as much as $9 billion which sparked a lawsuit from Pfizer.
Pfizer had additionally altered the supply it made in September of almost $4.9 billion to offer additional cash up entrance, Metsera had stated.
New York-based Pfizer stated in an e-mail that it was pleased with the phrases of the deal, and expects to shut the transaction shortly following the Metsera shareholder assembly on Nov. 13.
Novo Nordisk stated Saturday it will not enhance its supply and would go away the race to accumulate Metsera.
Novo’s proposed deal had concerned paying $62.20 in money for every Metsera share, up from its earlier bid of $56.50. The Danish drugmaker deliberate to tack on a contingent worth proper cost of $24, one other enchancment from its earlier bid, if sure improvement and regulatory milestones had been met.
© 2025 The Canadian Press
